How do you decide timing of adjuvant radiation with respect to chemotherapy for a patient with resected pancreatic adenocarcinoma with microscopic positive margins?

Level 1 evidence supports chemotherapy, FOLFIRINOX is the standard. The benefit of radiation is modest in comparison and based on post-hoc analysis of phase III trials (ESPAC-1, and others that are themselves nearly uninterpretable). The answer to this question is chemotherapy followed by restaging ...